JP2020517635A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020517635A5 JP2020517635A5 JP2019556860A JP2019556860A JP2020517635A5 JP 2020517635 A5 JP2020517635 A5 JP 2020517635A5 JP 2019556860 A JP2019556860 A JP 2019556860A JP 2019556860 A JP2019556860 A JP 2019556860A JP 2020517635 A5 JP2020517635 A5 JP 2020517635A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cancer
- cell
- combination
- car
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023054969A JP7620994B2 (ja) | 2017-04-21 | 2023-03-30 | 腫瘍溶解性ウイルス療法および免疫療法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762488181P | 2017-04-21 | 2017-04-21 | |
| US62/488,181 | 2017-04-21 | ||
| PCT/US2018/028577 WO2018195427A2 (en) | 2017-04-21 | 2018-04-20 | Oncolytic virotherapy and immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023054969A Division JP7620994B2 (ja) | 2017-04-21 | 2023-03-30 | 腫瘍溶解性ウイルス療法および免疫療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020517635A JP2020517635A (ja) | 2020-06-18 |
| JP2020517635A5 true JP2020517635A5 (enExample) | 2021-05-20 |
| JP7260173B2 JP7260173B2 (ja) | 2023-04-18 |
Family
ID=62196688
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019556860A Active JP7260173B2 (ja) | 2017-04-21 | 2018-04-20 | 腫瘍溶解性ウイルス療法および免疫療法 |
| JP2023054969A Active JP7620994B2 (ja) | 2017-04-21 | 2023-03-30 | 腫瘍溶解性ウイルス療法および免疫療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023054969A Active JP7620994B2 (ja) | 2017-04-21 | 2023-03-30 | 腫瘍溶解性ウイルス療法および免疫療法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11896634B2 (enExample) |
| EP (1) | EP3612202A2 (enExample) |
| JP (2) | JP7260173B2 (enExample) |
| KR (2) | KR20240093758A (enExample) |
| CN (1) | CN110785180B (enExample) |
| AU (2) | AU2018254566B2 (enExample) |
| CA (1) | CA3060573A1 (enExample) |
| NZ (1) | NZ758626A (enExample) |
| SG (1) | SG11201909749PA (enExample) |
| TW (1) | TWI799411B (enExample) |
| WO (1) | WO2018195427A2 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201507393TA (en) | 2013-03-14 | 2015-10-29 | Salk Inst For Biological Studi | Oncolytic adenovirus compositions |
| PL3198009T3 (pl) | 2014-09-24 | 2022-01-24 | Salk Institute For Biological Studies | Onkolityczne wirusy nowotworowe i sposoby zastosowania |
| GB201500319D0 (en) * | 2015-01-09 | 2015-02-25 | Agency Science Tech & Res | Anti-PD-L1 antibodies |
| JP7054527B2 (ja) | 2016-02-23 | 2022-04-14 | ソーク インスティテュート フォー バイオロジカル スタディーズ | アデノウイルスの複製動態を測定するための高スループットアッセイ |
| JP7015551B2 (ja) | 2016-02-23 | 2022-02-15 | ソーク インスティテュート フォー バイオロジカル スタディーズ | ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現 |
| WO2018111767A1 (en) | 2016-12-12 | 2018-06-21 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
| JP7260173B2 (ja) * | 2017-04-21 | 2023-04-18 | ベイラー カレッジ オブ メディスン | 腫瘍溶解性ウイルス療法および免疫療法 |
| SG10201801219VA (en) * | 2018-02-13 | 2019-09-27 | Agency Science Tech & Res | Anti-HER2 Antibodies |
| JP7430395B2 (ja) | 2018-04-09 | 2024-02-13 | ソーク インスティテュート フォー バイオロジカル スタディーズ | 複製特質が増強された腫瘍溶解性アデノウイルス組成物 |
| WO2019202118A1 (en) * | 2018-04-20 | 2019-10-24 | Baylor College Of Medicine | Oncolytic virotherapy and immunotherapy |
| US11413315B2 (en) * | 2018-04-29 | 2022-08-16 | City Of Hope | Neural stem cell-mediated cancer treatment |
| TWI856035B (zh) * | 2018-10-25 | 2024-09-21 | 貝勒醫學院 | 溶瘤病毒療法及免疫療法 |
| SG11202108398YA (en) * | 2019-02-01 | 2021-08-30 | Novarock Biotherapeutics Ltd | Anti-claudin 18 antibodies and methods of use thereof |
| CN111743923B (zh) * | 2019-03-27 | 2024-11-08 | 北京康万达医药科技有限公司 | 包含分离的重组溶瘤腺病毒和免疫细胞的治疗剂及其应用 |
| AU2020266125B2 (en) * | 2019-04-29 | 2023-04-13 | Mayo Foundation For Medical Education And Research | Multivalent PD-L1 binding compounds for treating cancer |
| WO2021091560A1 (en) * | 2019-11-07 | 2021-05-14 | Baylor College Of Medicine | Oncolytic virotherapy and immunotherapy |
| CN111632146B (zh) * | 2020-05-29 | 2021-09-28 | 中山大学 | Oat抑制剂和溶瘤病毒在制备抗肿瘤药物中的应用 |
| CN111676245B (zh) * | 2020-06-24 | 2022-09-13 | 武汉波睿达生物科技有限公司 | 一种含有HSV-1型溶瘤病毒的NFAT-Cre-CAR-T细胞及其应用 |
| CN113913379B (zh) * | 2020-07-07 | 2024-02-06 | 深圳市菲鹏生物治疗股份有限公司 | T淋巴细胞及其应用 |
| CN113425856B (zh) * | 2021-07-07 | 2022-01-04 | 浙江康佰裕生物科技有限公司 | 一种含有基因修饰的溶瘤病毒的药物组合物及其在治疗癌症的用途 |
| WO2023076469A1 (en) * | 2021-10-29 | 2023-05-04 | Unm Rainforest Innovations | Oncolytic virotherapy compositions and methods |
| CN114032323B (zh) * | 2021-11-17 | 2023-08-08 | 云南省烟草农业科学研究院 | 一种与雪茄烟抗黑胫病基因紧密连锁的共显性ssr标记及其应用 |
| WO2024042231A1 (en) * | 2022-08-26 | 2024-02-29 | Universite De Namur | Adenovirus-based adjuvants for cancer treatment |
| CN116196402A (zh) * | 2022-11-01 | 2023-06-02 | 山东大学齐鲁医院 | 表达双特异性抗体的溶瘤腺病毒联合cart在肿瘤治疗中的应用 |
| EP4704890A1 (en) * | 2023-05-03 | 2026-03-11 | Mayo Foundation for Medical Education and Research | Methods and materials for treating cancer |
| CN118930652B (zh) * | 2024-07-29 | 2025-03-11 | 北京肿瘤医院(北京大学肿瘤医院) | 一种免疫检查点pd-l2靶向单链抗体及放射性核素标记物与应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0931830T3 (da) | 1993-02-16 | 2001-06-11 | Onyx Pharma Inc | Cytopatiske vira til terapi og profylakse af neoplasi |
| US7045347B2 (en) | 1993-06-24 | 2006-05-16 | Advec, Inc. | Helper dependent adenovirus vectors based on integrase family site-specific recombinases |
| US6730507B1 (en) | 1993-06-24 | 2004-05-04 | Merck & Co., Inc. | Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration |
| US6080569A (en) | 1993-06-24 | 2000-06-27 | Merck & Co., Inc. | Adenovirus vectors generated from helper viruses and helper-dependent vectors |
| US5919676A (en) | 1993-06-24 | 1999-07-06 | Advec, Inc. | Adenoviral vector system comprising Cre-loxP recombination |
| ATE304604T1 (de) | 1993-06-24 | 2005-09-15 | Frank L Graham | Adenovirus vektoren für gentherapie |
| AU4592697A (en) | 1996-09-24 | 1998-04-17 | Dana-Farber Cancer Institute | Method of targeting malignant cells using an e2f responsive promoter |
| US20030017138A1 (en) | 1998-07-08 | 2003-01-23 | Menzo Havenga | Chimeric adenoviruses |
| US20060275262A1 (en) | 2001-07-26 | 2006-12-07 | Mathis James M | Conditionally replicating viruses and methods for cancer virotherapy |
| KR100523028B1 (ko) | 2003-02-27 | 2005-10-20 | 윤채옥 | 개선된 암세포 특이성과 활성을 가지는 사람 텔로미어역전사효소 프로모터 및 이를 포함하는 재조합 벡터 |
| WO2005086922A2 (en) * | 2004-03-10 | 2005-09-22 | Board Of Regents, University Of Texas System | Oncolytic adenovirus armed with therapeutic genes |
| JP2012513209A (ja) | 2008-12-22 | 2012-06-14 | オンコス セラピュティックス オサケ ユキチュア | 腫瘍溶解アデノウイルスベクター並びに前記に関連する方法および使用 |
| EP2619224A1 (en) | 2010-09-24 | 2013-07-31 | Oncos Therapeutics Oy | Oncolytic adenoviral vectors and methods and uses related thereto |
| BR112013006699A2 (pt) | 2010-09-24 | 2016-06-14 | Oncos Therapeutics Oy | vetor adenoviral oncolítico que codifica anticorpos anti-ctl4-4 monoclonais, célula e composição farmacêutica compreendendo o mesmo, método de produção de anticorpo monoclonal humano específico para ctla-4 em uma célula e uso do referido vetor adenoviral |
| FI123955B (en) | 2011-11-25 | 2014-01-15 | Oncos Therapeutics Ltd | Oncolytic adenovirus |
| PL2623604T3 (pl) | 2012-02-02 | 2015-07-31 | Baylor College Medicine | Biologiczny system dostarczania i ekspresji oparty na adenowirusie do zastosowania w leczeniu choroby zwyrodnieniowej stawów |
| PL2948553T3 (pl) | 2013-01-25 | 2020-11-16 | Baylor College Of Medicine | Adenowirusowy system dostarczania i ekspresji terapii genowej zależny od pomocnika |
| SG11201507393TA (en) * | 2013-03-14 | 2015-10-29 | Salk Inst For Biological Studi | Oncolytic adenovirus compositions |
| GB201500319D0 (en) | 2015-01-09 | 2015-02-25 | Agency Science Tech & Res | Anti-PD-L1 antibodies |
| CN106831987B (zh) * | 2015-12-04 | 2020-01-21 | 浙江大学 | 一种抗人her2抗体及其编码基因和应用 |
| CN106831986B (zh) * | 2015-12-04 | 2020-01-21 | 浙江大学 | 一种抗人her2抗体及其编码基因和应用 |
| JP7260173B2 (ja) * | 2017-04-21 | 2023-04-18 | ベイラー カレッジ オブ メディスン | 腫瘍溶解性ウイルス療法および免疫療法 |
-
2018
- 2018-04-20 JP JP2019556860A patent/JP7260173B2/ja active Active
- 2018-04-20 AU AU2018254566A patent/AU2018254566B2/en active Active
- 2018-04-20 WO PCT/US2018/028577 patent/WO2018195427A2/en not_active Ceased
- 2018-04-20 US US16/607,066 patent/US11896634B2/en active Active
- 2018-04-20 TW TW107113504A patent/TWI799411B/zh active
- 2018-04-20 KR KR1020247016403A patent/KR20240093758A/ko active Pending
- 2018-04-20 SG SG11201909749P patent/SG11201909749PA/en unknown
- 2018-04-20 EP EP18725690.4A patent/EP3612202A2/en active Pending
- 2018-04-20 CN CN201880042149.2A patent/CN110785180B/zh active Active
- 2018-04-20 CA CA3060573A patent/CA3060573A1/en active Pending
- 2018-04-20 KR KR1020197033577A patent/KR102830905B1/ko active Active
- 2018-04-20 NZ NZ758626A patent/NZ758626A/en unknown
-
2019
- 2019-06-03 US US16/430,347 patent/US10716818B2/en active Active
-
2023
- 2023-03-30 JP JP2023054969A patent/JP7620994B2/ja active Active
-
2025
- 2025-05-09 AU AU2025203355A patent/AU2025203355A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Diaz Arguello et al. | Apoptosis-inducing TNF superfamily ligands for cancer therapy | |
| JP2013107899A5 (enExample) | ||
| Liu et al. | Gene-based vaccines and immunotherapeutics | |
| JP2008056679A5 (enExample) | ||
| JP2011521662A5 (enExample) | ||
| JP2017537622A5 (enExample) | ||
| JP2019531728A5 (enExample) | ||
| JP2022514420A5 (enExample) | ||
| JP2015096070A5 (enExample) | ||
| JP2017513502A5 (enExample) | ||
| CN102633883A (zh) | 一种能与egfr、her2、vegf高效结合的融合蛋白、其编码序列及用途 | |
| JP2015509707A5 (enExample) | ||
| JP2019531093A5 (enExample) | ||
| JP2016505635A5 (enExample) | ||
| JP2021533789A5 (enExample) | ||
| RU2015155821A (ru) | Вакцины против малярии | |
| JP2010519931A5 (enExample) | ||
| CN112154204A (zh) | 基因工程化的细胞及应用 | |
| JP2013517783A5 (enExample) | ||
| JP2016513471A5 (enExample) | ||
| JP2019519529A5 (enExample) | ||
| JP2022536929A5 (enExample) | ||
| JP2016128513A5 (enExample) | ||
| JP2018505893A5 (enExample) | ||
| JP2017507943A5 (enExample) |